Open AccessSix-Month Open-Label Follow-Up of Risperidone Long-Acting Injection Use in Pediatric Bipolar Disorder
Author(s) -
Miguel Angelo Boarati,
YuanPang Wang,
Ana Paula Ferreira-Maia,
Ana Rosa S. Cavalcanti,
Lee FuI
Publication year - 2013
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.12m01368
Subject(s) - risperidone , bipolar disorder , open label , medicine , pediatrics , psychiatry , schizophrenia (object oriented programming) , pharmacology , adverse effect , mood
Recent studies suggest that risperidone long-acting injection (RLAI) may be considered for controlling mood episodes in bipolar disorder patients who have relapsed due to medication nonadherence or failure to respond to standard therapies. Currently, no study has reported the usefulness of RLAI in youths with bipolar disorder. The aim of this study was to evaluate short-term effects of RLAI in the naturalistic treatment of early-onset bipolar disorder and its role in symptomatic remission and adherence to treatment.